

REFERENCES

- Adams KF, Schatzkin A, Harris TB, et al(2006):** Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old N Engl J Med 2006;355:763–778
- Adams RJ, Albers G, Alberts MJ, et al.(2008):** Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke;39:1647–52.
- Ajjan, R. A., & Grant, P. J. (2005).** Role of clotting factors and fibrin structure in predisposition to atherothrombotic disease. Expert Rev Cardiovasc Ther 3, 1047-1059.
- Alimento M, Campodonico J, Santambrogio Get al.(1997)** The antagonistic effect of aspirin on the expression of prostaglandin participation in the antihypertensive activity of ACE inhibitors [in Italian]. Cardiologia. 1997;42:605-610.
- Allison MA, Hiatt WR, Hirsch AT, Coll JR, Criqui MH (April 2008).** "A high ankle-brachial index is associated with increased cardiovascular disease morbidity and lower quality of life". J Am Coll Cardiol. 51 (13): 1292–8.
- Andreadis EA, Tsourous GI, Marakomichelakis GE, et al (2005).** High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. J Hum Hypertens. 2005;19:491–6.
- Antman EM, Hand M, Armstrong PW, et al. (2007)** focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2007;117:296–329.

- Antman EM, Wiviott SD, Murphy SA, et al.(2008)** Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel – Thrombolysis In Myocardial Infarction) analysis. *J Am Coll Cardiol.* 2008;51:2028–2033.
- Arad Y et al. (2005)** Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. *J Am Coll Cardiol* 46: 158–165
- Arnlov J et al. (2005)** Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. *Circulation* 112: 969–97
- Autier P, Gandini S.(2007)** Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. *Arch Intern Med.* 2007;167(16):1730-1737
- Baigent, C., Keech, A., Kearney, P. M., Blackwell, L., Buck, G., Pollicino, C., et al. (2005).** Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. *Lancet* 366, 1267-1278.
- Bakris GL, Fonseca V, Katholi RE, et al. (2004)** GEMINI Investigators Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA*;292(18):2227-2236
- Ballantyne CM, Raichlen JS, Nicholls SJ, et al.(2008)** ASTEROID Investigators Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of

rosuvastatin on intravascular ultrasound-derived coronary atheroma burden.
Circulation 2008. May;117(19):2458-2466 Epub 2008 Mar 31 [PubMed]

Barnett HJ, Taylor DW, Eliasziw M et al (1998) Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N. Engl. J. Med. 1998;339:1415–1425.

Barter PJ, Caulfield M, Eriksson M, Grundy SM, et al (2007) ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122.

Barter PJ, Rye KA (March 2006). "Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?". Circulation 113 (12): 1553–5. doi:10.1161/CIRCULATIONAHA.105.620450. PMID 16567579. <http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=16567579>.

Barton Duell P, Connor WE. (2008) Vitamin D deficiency is associated with myalgias in hyperlipidemic subjects taking statins [abstract 3701]. Circulation 2008;118:S470 .

Bays HE, Davidson M, Jones MR, Abby SL. (2006) Effects of colesvelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia [published correction appears in Am J Cardiol. 2006;98(3):428] Am J Cardiol. 2006. Apr 15;;97(8):1198-1205 Epub 2006 Mar 3

Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB (1999). "Reye's syndrome in the United States from 1981 through 1997". N. Engl. J. Med. 340 (18): 1377–82. doi:10.1056/NEJM199905063401801. PMID 10228187

Belhassen L, Pelle G, Dubois Rande JL, Adnot S (2003). Improved endothelial function by the thromboxane A2 receptor antagonist S18886 in patients with

coronary artery disease treated with aspirin. *J Am Coll Cardiol.* 2003;41:1198–204. doi: 10.1016/S0735-1097(03)00048-2.

Bell DS, O'Keefe JH, Jellinger P. (2008) Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? *Endocr Pract.* 2008;14(1):112-124

Benatar, JR; Stewart, RA (2007). "Is it time to stop treating dyslipidaemia with fibrates?". *The New Zealand medical journal* **120** (1261):U2706.PMID 17853928.<http://www.nzma.org.nz/journal/120-1261/2706/>.

Berenson, A (2008-01-14). "Drug Has No Benefit in Trial, Makers Say". *NY Times*. <http://www.nytimes.com/2008/01/14/business/14cnd-drug.html?em&ex=1200459600&en=fe4f047fcd65a68e&ei=5070>. Retrieved 2008-01-14.

Berger JS, Brown DL, Becker RC.(2008) Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. *Am J Med* 2008;121:43–9.

Berges-Gimeno MP & Stevenson DD (2004). "Nonsteroidal anti-inflammatory drug-induced reactions and desensitization". *J Asthma* **41** (4): 375–84. doi:10.1081/JAS-120037650. PMID 15281324

Bhatt DL et al. (2006) International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. *JAMA* **295**: 180–189

Bhatt DL, Scheiman J, Abraham NS, et al.(2008) ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology foundation task force on clinical expert consensus documents. *Circulation* 2008;118:1894–909.

- Bloomfield D, Carlson GL, Sapre A, Tribble D,(2009).** Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. *Am Heart J.* 2009;157:352–360.e2. [PubMed]
- Boden WE.(2000)** High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial. *Am J Cardiol.* 2000;86:19L–22L. doi: 10.1016/S0002-9149(00)01464-8. [PubMed] [Cross Ref]
- Boersma E, Harrington RA, Moliterno DJ et al.(2002)** Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials [published correction appears in *Lancet.* 2002;359:2120]. *Lancet.* 2002;359:189-198.
- Bonora E, Corrao G, Bagnardi V, et al.(2006)** Prevalence and correlates of postprandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. *Diabetologia* 2006. May;49(5):846-854 Epub 2006 Mar 11
- Bousser MG, Amarenco P, Chamorro A, et al.(2009)** : the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. *Cerebrovasc Dis.*;27:509–518.
- Braunwald E, Antman EM, Beasley JW et al (2002).** ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—. *J Am Coll Cardiol.* 2002;40:1366-1374.
- Brenner BM, Cooper ME, de Zeeuw D, et al (2001).** Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med.* 2001;345:861–869. [PubMed]

- Brewer, H. Bryan (December 27, 2005).** "Raising HDL-Cholesterol and Reducing Cardiovascular Risk: An Expert Interview With H. Bryan Brewer, Jr, MD". <http://cme.medscape.com/viewarticle/520393>. Retrieved October 8, 2009.
- Burgess E, Bakris G, Weir M, Koval S (2007).** Comparative long term effects of two AT₁receptor blockers on proteinuria in patients with type-2 diabetes and overt nephropathy and hypertension: results of the AMADEO trial. *J Hypertens*. 2007;25(suppl 2):S276.
- Bybee KA, Lee JH, O'Keefe JH.(2008)** Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. *Curr Med Res Opin*. 2008. Apr;24(4):1217-1229
- Cai J et al. (2005)** In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: *Circulation* 112: 3437–3444
- Califf RM, Lokhnygina Y, Cannon CP, et al (2010)** An update on the improved reduction of outcomes: Vytarin Efficacy International Trial (IMPROVE-IT) design. *Am Heart J*. 2010;159(5):705–709. [[PubMed](#)]
- Campbell CL, Smyth S, Montalescot G, Steinhubl SR.(2007)** Aspirin dose for the prevention of cardiovascular disease: a systematic review. *JAMA* 2007;297:2018–2
- Campbell DJ, Woodward M, Chalmers JP, et al (2005)** Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease. *Circulation*. 2005;112:110–116.
- Cannon CP, Husted S, Harrington RA, et al.(2007)** Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-

- segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. *J Am Coll Cardiol.* 2007;50:1844–1851. [PubMed]
- CAPRIE Steering Committee (1996)** A randomized , blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) *Lancet.* 1996;348:1329–1339.
- Cardenas GA, Lavie CJ, Cardenas V, Milani RV, et al.,(2008)** The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. *Rev Cardiovasc Med.* 2008;9(4):239-258
- Carlberg B, Samuelsson O, Lindholm LH.(2005)** Atenolol in hypertension: is it a wise choice [published correction appears in *Lancet.*;365(9460):656]
- Carter BL, Ernst ME, Cohen JD. (2004)** Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. *Hypertension* Jan;43(1):4-9 Epub 2003 Nov 24
- Casscells, W., Naghavi, M., & Willerson, J. T. (2003).** Vulnerable atherosclerotic plaque: a multifocal disease. *Circulation* 107, 2072-2075.
- Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Ceriello A, Motz E.(2004)** Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited *Arterioscler Thromb Vasc Biol*;24:816-823.
- Chang YJ, Ryu SJ, Lee TH (2006).** Dose titration to reduce dipyridamole-related headache. *Cerebrovasc Dis* 2006;22:258–62.
- Chapman, M. J. (1999).** Atherogenicity of LDL. In P. Barter, & K. -A. Rye (Eds.), *Plasma Lipids and their Role in Disease*. Oxford, UK: Harwood Academic Publishers.

- Charles Z, Pugh E, Barnett D.(2008)** Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolemia: NICE technology appraisal guidance. *Heart*. 2008;**94**(5):642–643.
- Chassot PG, Delabays A, Spahn DR (2007).** Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. *Br J Anaesth* 2007;99:316–28.
- Cheng Y, Austin SC, Rocca B, et al.(2002)** Role of prostacyclin in the cardiovascular response to thromboxane A₂. *Science*. 2002;296:539–41. doi: 10.1126/science.1068711. [PubMed] [Cross Ref]
- Chiasson JL, Josse RG, Gomis R, et al (2002)** STOP-NIDDM Trial Research Group Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. *Lancet* 2002;359(9323):2072-2077
- Chobanian AV, Bakris GL, Black HR, et al (2003).** The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003;289:2560–72.
- Cleland JG, Coletta AP, Yassin A, et al. (2008)** Clinical trials update from the American College of Cardiology 2008: CARISMA, TRENDS, meta-analysis of Cox-2 studies, HAT, ON-TARGET, HYVET, ACCOMPLISH, MOMENTUM, PROTECT, HORIZON-HF and REVERSE. *Eur J Heart Fail* 2008. Jun;10(6):614-620 Epub 2008 May 27
- CohenA, Tzourio C, Bertrand B et al(1997):** Aortic plaque morphology and vascular events: a follow-up study in patients with ischemic stroke. FAPS Investigators. French Study of Aortic Plaques in Stroke. *Circulation*. 1997;96:3838–3841
- Colhoun HM, Betteridge DJ, Durrington PN, et al. (2004)** CARDS investigators Primary prevention of cardiovascular disease with atorvastatin in

- type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet*;364(9435):685-696
- Conaway DG, O'Keefe JH, Reid KJ, Spertus J.(2005)** Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome. *Am J Cardiol.* 2005;96(3):363-365
- Corti, R., Hutter, R., Badimon, J. J., & Fuster, V. (2004).** Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. *J Thromb Thrombolysis* 17, 35-44.
- Corti R, Fuster V, Badimon JJ(2003):** Pathogenetic concepts of acute coronary syndromes. *J. Am. Coll. Cardiol.*
- Creager MA, Luscher TF, Cosentino F, Beckman JA.(2003)** Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I *Circulation*;108:1527-1532.
- Critchley JA, Capewell S.(2003)** Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. *JAMA* 2003;290(1):86-97 [PubMed]
- Crouse JR, III, Raichlen JS, Riley WA, et al.(2007)** METEOR Study Group Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. *JAMA* 2007. Mar 28;;297(12):1344-1353 Epub 2007 Mar 25
- Cushman M et al. (2005)** C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the Cardiovascular Health Study. *Circulation* 112: 25–31
- Dahlöf B, Devereux RB, Kjeldsen SE, et al.(2002)** LIFE Study (LIFE): a randomised trial against atenolol. *Lancet* 2002;359(9311):995-1003 [PubMed]
- Dahlof B, Sever PS, Poulter NR, et al (2005).** Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as

required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet*. 2005;366:895–906.

Das S, O'Keefe JH.(2006) Behavioral cardiology: recognizing and addressing the profound impact of psychosocial stress on cardiovascular health. *Curr Atheroscler Rep*. 2006;8(2):111-118

Davidson KW, Kupfer DJ, Bigger JT, et al. (2006) Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute working group report. *Ann Behav Med*. 2006;32(2):121-126

Davies, M. J. (1996). Stability and instability, two faces of coronary atherosclerosis:The Dudley White Lecture.*Circulation* 49,2013-2020.

de Grooth GJ, Smilde TJ, Van Wissen S, Klerkx AH, Zwinderman AH,et al(2004). The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. *Atherosclerosis*. 2004;173:261–267. [PubMed]

de la Sierra A (2006). Angiotensin receptor blockers in hypertension and cardiovascular diseases. *Cardiovasc Hematol Agents Med Chem*. 2006;4:67–73. [PubMed]

Dentali F, Squizzato A, Ageno W (2009):The metabolic syndrome as a risk factor for venous and arterial thrombosis. *Semin Thromb Hemost.*; 35: 451–457.

Després, Jean-Pierre.(2009) "The Atherogenic Triad of New Metabolic Risk Factors: Importance of Waist and Fasting Triglycerides as Screening Tools". Visceral Adipose Tissue and Cardiometabolic Risk: Does It Really Matter? Part <http://www.lipidsonline.org/slides/slide01.cfm?q=apolipoprotein&dpg=59> Retrieved October 8, 2009

- Dicpinigaitis PV(2006).** Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. *Chest*. 2006;129(1 Suppl):169S–173S. [PubMed]
- Diener HC, Bogousslavsky J, Brass LM, et al.,(2004)** MATCH Investigators Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *Lancet*. 2004;364:331-337.
- Drexel, H. (2006).** "Reducing risk by raising HDL-cholesterol: the evidence". *European Heart Journal Supplements* **8**: F23. doi:10.1093/eurheartj/sul037.
- Dzau VJ, Bernstein K, Celermajer D, et al (2002)** Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. *Cardiovasc Drugs Ther*. 2002;16:149–160. [PubMed]
- Egan KM, Wang M, Fries S, et al.(2005)** Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. *Circulation*. 2005;111:334–42. doi: 10.1161/01.CIR.0000153386.95356.78.
- Ernst ME, Carter BL, Goerdt CJ, et al. (2006)** Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. *Hypertension*. Mar;47(3):352-358 Epub 2006 Jan 23
- Ferguson JJ, III, Chronos NAF, Harrington R et al., (2000)**The physiology of normal platelet function. In: Ferguson JJ, III, Chronos NAF, Harrington RA, eds. *Antiplatelet Therapy in Clinical Practice*. London, England: Martin Dunitz; 2000:15-34.
- Fiessinger JN. S18886(2004),** a new specific TP-receptor antagonist, is safe and as effective as aspirin in inhibiting platelet aggregation in patients with peripheral arterial disease. *Eur Heart J*. 2004;25:573.

- Fogoros, Richard N. (September 15, 2009).** "Raising Your HDL Levels".About.com.<http://heartdisease.about.com/cs/cholesterol/a/raiseHDL.htm>. Retrieved October 8, 2009.
- Fonarow GC, Wright RS, Spencer FA, et al.,(2005)** Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. *Am J Cardiol.* 2005;96:611–616. doi: 10.1016/j.amjcard.2005.04.029.
- Fonarow P, Alan D, Vejvoda J, Kukacka J et al,(2010).** Fluvastatin in the first-line therapy of Acute Coronary Syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (The FACS-trial) *Trials.* 2010
- Fowkes FG, Housley E, Riemersma RA, et al.(1992)** Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. *Am J Epidemiol.* 1992;135:331-340.
- Fox KA, Mehta SR, Peters R, et al.(2004)** Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non–ST-elevation acute coronary syndrome: the clopidogrel in unstable angina to prevent recurrent ischemic events (CURE) trial. *Circulation* 2004;110:1202–8.
- Fuster V, Gotto AM, Libby P, Loscalzo J, McGill HC (1996):** 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events, *J Am Coll Cardiol.* 1996;27:964-976.
- Fuster V and Kim RJ (2005)** Frontiers in cardiovascular magnetic resonance. *Circulation* 112: 135–144

- Giovannucci E, Liu Y, Hollis BW, Rimm EB (2008).** 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. *Arch Intern Med.* 2008;168(11):1174-1180
- Glynn RJ, Danielson E, Fonseca FA, et al. (2009)** A randomized trial of rosuvastatin in the prevention of venous thromboembolism. *N Engl J Med.* 2009. Apr 30;;360(18):1851-1861 Epub Mar 29 59.
- Goldberg RB, Jacobson TA.(2008)** Effects of niacin on glucose control in patients with dyslipidemia. *Mayo Clin Proc.* 2008;83(4):470-478
- Guitton MJ, Caston J, Ruel J, Johnson RM, Pujol R, Puel JL (2003).** "Salicylate induces tinnitus through activation of cochlear NMDA receptors". *J.Neurosci.*23(9):3944–52.PMID 12736364.
- Gurbel PA, Bliden KP, Butler K, et al.(2009)** Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study. *Circulation.* 2009;120:2511–2522.
- Haberl R et al. (2005)** Multislice spiral computed tomographic angiography of coronary arteries in patients with suspected coronary artery disease: an effective filter before catheter angiography? *Am Heart J* 149: 1112–1119
- Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A (2006).** Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. *Lancet* 2006;367:1665–73.
- Hamilton-Craig I, Kostner K, Colquhoun D, Woodhouse S (2009)**At sea with SEAS: the first clinical endpoint trial for ezetimibe, treatment of patients with mild to moderate aortic stenosis, ends with mixed results and more controversy. *Heart Lung Circ.* 2009;**18**(5):343–346. [[PubMed](#)]

- Hankey GJ, Sudlow CL. Dunbabin DW (2000)** Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. *Stroke*. 2000;31:1779-1784.
- Hansson, G. K. (2005).** Inflammation, atherosclerosis and coronary artery disease. *N Engl J Med*;352:1685-169
- Harrington RA, Stone GW, McNulty S, et al.(2009)** Platelet inhibition with cangrelor in patients undergoing PCI. *N Engl J Med*. 2009;361:2318–2329.
- HarrisonP, Frelinger AL III, Furman MI, Michelson AD. (2007)** Measuring antiplatelet drug effects in the laboratory. *Thromb Res* (2007) 120:323–336.
- Hayden M, Pignone M, Phillips C, Mulrow C (2002)** Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2002;136:161-172.
- He FJ, MacGregor GA(2004)** Effect of longer-term modest salt reduction on blood pressure. *Cochrane Database of Systematic Reviews* 2004, Issue 1. Art. No.: CD004937. DOI: 10.1002/14651858.CD004937.
- Helgason CM, Bolin KM, Hoff JA et al (1994).** Development of aspirin resistance in persons with previous ischemic stroke. *Stroke*. 1994;25:2331-2336.
- Helton TJ, Bavry AA, Kumbhani DJ, et al.,(2007)** Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. *Am J Cardiovasc Drugs* 2007;7:289–97.
- Holick MF (March 1995).** "Environmental factors that influence the cutaneous production of vitamin D". *The American Journal of Clinical Nutrition* 61 (3 Suppl): 638S–645S. PMID 7879731.
- Holick MF.(2006)** High prevalence of vitamin D inadequacy and implications for health. *Mayo Clin Proc*. 2006;81(3):353-373

Holick MF (2007). Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281

Husted S, Emanuelsson H, Heptinstall S, et al.,(2006) Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y₁₂ antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038–47.

Hutter VC R, Sauter BV, et al. (2004) Caspase-3 and tissue factor expression in lipid-rich plaque macrophages: evidence for apoptosis as a link between inflammation and atherothrombosis Circulation;109:2001-2008.

Jakubowski JA, Matsushima N, Asai F, et al.(2007) A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y₁₂ inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 2007;63:421–30

Jamerson K, Weber MA, Bakris GL, et al.(2008) ACCOMPLISH Trial Investigators Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med;359(23):2417-2428

Jneid H, Thacker HL(2001) Coronary artery disease in women: different, often undertreated. Cleve Clin J Med. 2001;68(5):441-448.

John D. Brunzell, FACP, Michael Davidson, MD, FACC, et al(2008)Lipoprotein Management in Patients With Cardiometabolic Risk, J Am Coll Cardiol, 2008; 51:1512-1524.

Jones, P., Kafonek, S., Laurora, I., & Hunninghake, D. (1998). Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81, 582-587.

Julius S, Kjeldsen SE, Weber M, et al. (2004) VALUE trial group Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet;363(9426):2022-2031

- Jun M, Foote C, Lv J, et al. (2010).** "Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis". *Lancet* 375 (9729): 1875–1884. doi:10.1016/S0140-6736(10)60656-3.
- Kahn SE, Haffner SM, Heise MA, et al (2007)**ADOPT study Group Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [published correction appears in *N Engl J Med*. 2007;356(13):1387-1388]
- Kaiser C et al. (2005)** Limited diagnostic yield of non-invasive coronary angiography by 16-slice multidetector spiral computed tomography in routine patients referred for evaluation of coronary artery disease. *Eur Heart J* 26: 1987–1992
- Kaplan NM (2008)** Beta blockers in hypertension: adding insult to injury. *J Am Coll Cardiol*. 2008;52(18) :1490-1491
- Kawasaki, M., Sano, K., Okubo, M., Yokoyama, H., Ito, Y., Murata, I., et al. (2005).** Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. *J Am Coll Cardiol* 45, 1946-1953.
- Kefer J et al (2005)** Head-to-head comparison of three dimensional navigator-gated magnetic resonance imaging and 16-slice computed tomography to detect coronary artery stenosis in patients. *J Am Coll Cardiol* 46: 92–100
- Khera A et al (2006)** Relationship between C-reactive protein and subclinical atherosclerosis. The Dallas Heart Study. *Circulation* 113: 38–43
- King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. (2007)** focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. *Circulation* 2007;117:261–95.

- Kistorp C et al (2005)** N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. *JAMA* 293: 1609–1616
- Klapholz M (2009)** β -Blocker use for the stages of heart failure. *Mayo Clin Proc.*;84(8):718-729
- Klein S, Burke LE, Bray GA, et al (2004)** American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. *Circulation*. 2004;110(18):2952–2967. [PubMed]
- Kohlstedt K, Busse R, Fleming I(2005).** Signaling via the angiotensin-converting enzyme enhances the expression of cyclooxygenase-2 in endothelial cells. *Hypertension*. 2005;45:126–132. [PubMed]
- Kraitchman DL et al. (2005)** Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. *Circulation* 112: 1451–1461
- Kress AM, Hartzel MC, Peterson MR (2003)** Burden of disease associated with overweight and obesity among U.S. military retirees and their dependents, aged 38-64, 2003. *Prev Med*. 2005;41(1):63–69.
- Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, et al(2007)**Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. *Lancet*. 2007;370:1907–1914.
- Ku, D. N., Giddens, D. P., Zarins, C. K., & Glagov, S. (1985).** Pulsatile flow and atherosclerosis in the human carotid bifurcation. Positive correlation between plaque location and low oscillating shear stress. *Arteriosclerosis* 5, 293-302.

- Kuivenhoven JA, de Grooth GJ, Kawamura H, Klerkx AH, Wilhelm F, et al(2005).** Effectiveness of inhibition of cholesteryl ester transfer protein by JTT 705 in combination with pravastatin in type II dyslipidemia. *Am J Cardiol.* 2005;95:1085–1088. [PubMed]
- Kuwahara M, Sugimoto M, Tsuji S et al.(2002)** Platelet shape changes and adhesion under high shear flow. *Arterioscler Thromb Vasc Biol.* 2002;22:329-334
- Kwiterovich Jr, PO (2000).** "The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review". *The American journal of cardiology* **86** (12A): 5L–10L. doi:10.1016/S0002-9149(00)01461-2. PMID 11374859. edit
- Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al.(2007)** Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. *Am J Gastroenterol* 2007;102:507–15.
- LaRosa JC, Grundy SM, Waters DD, et al (2005)** Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med.* Apr 7;;352(14):1425-1435 Epub 2005 Mar 8
- Lavie CJ, Milani RV, Ventura HO(2009)** LObesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. *J Am Coll Cardiol.* 2009;53(21):1925-1932
- Leal, J., Luengo-Fernandez, R., Gray, A., Petersen, S., & Rayner, M. (2006).** Economic burden of cardiovascular diseases in the enlarged European Union. *Eur Heart J* 27, 1610-1619.

- Leber AW et al. (2006)** Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: a comparative study using intravascular ultrasound. *J Am* 10/23/2010
- Leclerc JR (2002)** Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions. *Crit Care Med.* 2002;30(5, suppl.):S332-S340.
- Lee JH, Jones PG, Bybee KA, O'Keefe JH.(2008)**A longer course of varenicline therapy improves smoking cessation rates. *Prev Cardiol.* 2008;11(4):210-214
- Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF.(2008)**Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? *J Am Coll Cardiol.* 2008;52(24):1949-1956
- Lee JH, O'Keefe JH, Lavie CJ, Marchioli R, Harris WS(2008)** Omega-3 fatty acids for cardioprotection [published correction appears in *Mayo Clin Proc.* 2008;83(6):730] *Mayo Clin Proc.* 2008;83(3):324-332
- Leenen FH (2004).** Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome. *Can J Cardiol.* 2004;20(Suppl B):77B–82B.
- Leong-Poi H et al. (2005)** Assessment of endogenous and therapeutic arteriogenesis by contrast ultrasound molecular imaging of integrin expression. *Circulation* 111: 3248–3254
- Lester SJ, Eleid MF, Khandheria BK, Hurst RT.(2009)** Carotid intima-media thickness and coronary artery calcium score as indications of subclinical atherosclerosis. *Mayo Clin Proc.*;84(3):229-233
- Lewin AJ, Kipnes MS, Meneghini LF, et al.(2004)** Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: a

multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther.;26:379-389.

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.

Li YC, Kong J, Wei M, et al (2002). 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110:229–38. [PMC free article] [PubMed]

Libby, P., and Theroux, P. (2005). Pathophysiology of coronary artery disease. Circulation 111, 3481-3488.

Lichtenstein AH, Appel LJ, Brands M, et al.(2006) Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006. Jul 4;;114(1):82-96 Epub 2006 Jun 19

Linz W, Wohlfart P, Scholkens BA, et al (1999). Interactions among ACE, kinins and NO. Cardiovasc Res. 1999;43:549–561. [PubMed]

Liu E, Meigs JB, Pittas AG, et al (2009). Plasma 25-hydroxyvitamin d is associated with markers of the insulin resistant phenotype in nondiabetic adults. J Nutr. 2009;139:329–34. [PMC free article] [PubMed]

Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ (May 2006). "Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data". Lancet 367 (9524): 1747–57.

Lusis, A. J. (2000). pathophysiology of Atherosclerosis. Nature 407, 233-240.

MacFadyen RJ, Lee AFC, Morton JJ, et al (1999). How often are angiotensin II concentrations and aldosterone concentrations raised during chronic ACE

inhibitor treatment in cardiac failure? *Heart*. 1999;82:57–61. [PMC free article] [PubMed]

MagyarMT, SzikszaiZ, BallaJ et al(2003): Early-onset carotid atherosclerosis is associated with increased intima-media thickness and elevated serum levels of inflammatory markers. *Stroke*. 2003;34:58–63.

Mallat, Z., and Tedgui, A. (2000). Apoptosis in the vasculature: mechanisms and functional importance. *Br J Pharmacol* 130, 947-962.

Mancia G, De Backer G, Dominiczak A, et al. (2007) Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) *J Hypertens*. 2007;25:1105–87.

Mann JF, Schmieder RE, McQueen M, et al(2008) . ONTARGET investigators Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. *Lancet* 2008;372(9638):547-553 .

McInnes GT (2004) How important is optimal blood pressure control? *Clin Ther*. 2004;26(Suppl. A):A3–11. [PubMed]

McQuaid KR, Laine L(2006). Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. *Am J Med* 2006;119:624–38.

MCushman WC, Ford CE, Cutler JA, et al.(2003) ALLHAT Collaborative Research Group Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *J Clin Hypertens (Greenwich)* 4(6):393-404 ay 21;;289(19):2560-2572 Epub 2003 May 14

Meadows TA, Bhatt DL(2007): Clinical aspects of platelet inhibitors and thrombus formation. *Circ Res* 2007;100:1261–75

- Mehta RH, Roe MT, Mulgund J, et al.(2006)** Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. *J Am Coll Cardiol* 2006;48:281–6.
- Mehta SK, McCrary JR, Frutkin AD, et al.(2007)** Intravascular ultrasound radiofrequency analysis of coronary atherosclerosis: an emerging technology for the assessment of vulnerable plaque. *Eur Heart J.* 2007;28:1283–1288. doi: 10.1093/eurheartj/ehm112.
- Mehta, S. R., & Yusuf, S. (2003).** Short-and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. *J Am Coll Cardiol* 41(suppl S), 79S-88S.
- Meyers, C. Daniel; Carr, Molly C.; Park, Sang; Brunzell, John D. (2003).** "Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia". *Annals of Internal Medicine* 139 (12): 996. PMID 14678919. <http://www.annals.org/cgi/content/abstract/139/12/996>.
- Meyers, CD; Kamanna, VS; Kashyap, ML (2004).** "Niacin therapy in atherosclerosis". *Current opinion in lipidology* 15 (6): 659–65. doi:10.1097/00041433-200412000-00006. PMID 15529025.
- Mieghem CA, McFadden EP, Feyter PJ, et al.(2006)** Noninvasive detection of subclinical coronary atherosclerosis coupled with assessment of changes in plaque characteristics using novel invasive imaging modalities: the Integrated Biomarker and Imaging Study (IBIS) *J Am Coll Cardiol.* 2006;47:1134–1142. doi: 10.1016/j.jacc.2005.09.075. [PubMed] [Cross Ref]
- Miller GJ.(1992)** Hemostasis and cardiovascular risk. The British and European experience. *Arch Pathol Lab Med.* 1992;1 16:1318-1321.
- MirkhelA, Peyster E, Sundeen J, Greene L, Michelson AD, Hasan A, Domanski M. (2006)** Frequency of aspirin resistance in a community hospital. *Am J Cardiol* (2006) 98:577–579.

- Modi P.(2007)** Diabetes beyond insulin: review of new drugs for treatment of diabetes mellitus. *Curr Drug Discov Technol.* 2007;4(1):39-47
- Mollet NR et al. (2005)** High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography. *Circulation* 112: 2318–2323
- Monnier L, Lapinski H, Colette C.(2003)** Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). *Diabetes Care* 2003;26(3):881-885
- Musunuru K, Kral BG, Blumenthal RS, et al. (2008)** The use of high-sensitivity assays for C-reactive protein in clinical practice. *Nat Clin Pract Cardiovasc Med.* 2008. Oct;5(10):621-635 Epub 2008 Aug 19
- Mutin M, Canavy 1, Blann A, et al.(1999)** Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. *Blood.* 1999;93:2951-2958.
- Naghavi M, Libby P, Falk E, Casscells SW et al., (2003)** From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. *Circulation.* 2003;108:1664–72
- Nagy, L., Tontonoz, P., Alvarez, J. G. A., (1998).**Oxidised LDL regulates macrophage gene expression through ligand activation of PPAR. *Cell* 93, 229-240.
- Nasu K, Tsuchikane E, Katoh O, et al.(2006)** Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology compared with in vitro histopathology. *J Am Coll Cardiol.* 2006;47:2405–2412. doi: 10.1016/j.jacc.2006.02.044. [PubMed] [Cross Ref]
- Ndrepepa G et al. (2005)** Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. *Circulation* 112: 2102–2107

- Neal B, MacMahon S, Chapman N(2000).** Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. *Lancet*. 2000;356:1955–64.
- Nelson, Mark (2010)** "Drug treatment of elevated blood pressure". *AustralianPrescriber*(33):108112<http://www.australianprescriber.com/magazine/33/4/108/12>. Retrieved August 11, 2010.
- Neutel JM (2002).** The use of combination drug therapy in the treatment of hypertension. *Prog Cardiovasc Nurs*. 2002;17:81–8.
- Nicholls SJ, Tuzcu EM, Crowe T, et al.(2006)** Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound *J Am Coll Cardiol* 2006;47:1967–1975.
- Niitsu Y, Jakubowski JA, Sugidachi A, Asai F (2005)** Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y₁₂ receptor antagonist activity. *Semin Thromb Hemost*. 2005;31:184-194.
- Nissen, S. E. (2005).** Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. *Am J Cardiol* 118(12A), 22S-27S.
- Nissen, S. E. (2002).** Who is at risk for atherosclerotic disease? Lessons from intravascular ultrasound. *Am J Med* 112(suppl 8A), 27S-33S.
- Nissen SE, Nicholls SJ, Sipahi I, et al.(2006)** ASTEROID Investigators Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. *JAMA* Apr 5;;295(13):1556-1565
- Nissen SE, Tuzcu EM, Libby P, et al (2004).** Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. *JAMA*. 2004;292:2217–25.

- Nissen SE, Tuzcu EM, Schoenhagen P, et al. (2004)** REVERSAL Investigators
Effect of intensive compared with moderate lipid-lowering therapy on
progression of coronary atherosclerosis: a randomized controlled trial. JAMA
2004;291(9):1071-1080
- O'Donoghue M et al. (2006)** Lipoprotein-associated phospholipase A2 and its
association with cardiovascular outcomes in patients with acute coronary
syndromes in the PROVE IT-TIMI 22. Circulation 113: 1745–1752
- O'Hare AM, Katz R, Shlipak MG, Cushman M, Newman AB.(2006)** Mortality
and cardiovascular risk across the ankle-arm index spectrum: results from the
Cardiovascular Health Study Circulation 2006;113:388–393.
- O'Keefe JH, Bybee KA, Lavie CJ.(2008)** Intensive lipid intervention in the post-
ENHANCE era [editorial]. Mayo Clin Proc. 2008;83(8):867-869
- O'Keefe JH, Carter MD, Lavie CJ, Bell DS.(2009)** The gravity of JUPITER
(Justification for the Use of Statins in Primary Prevention: an Intervention
Trial Evaluating Rosuvastatin). Postgrad Med.;121(3):113-118
- O'Keefe JH, Cordain L, Harris WH, Moe RM,(2004)** . Optimal low-density
lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am
Coll Cardiol.;43(11):2142-2146
- O'Keefe JH, Gheewala NM, O'Keefe JO.(2008)** Dietary strategies for improving
post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am
Coll Cardiol. 2008;51(3):249-255
- O'Keefe JH, Jr, Poston WS, Haddock CK, ET AL (2004)** Psychosocial stress
and cardiovascular disease: how to heal a broken heart. Compr Ther.
2004;30(1):37-43
- O'LearyDH, Polak JF, Kronmal RA et al (1999)** Carotid-artery intima and
media thickness as a risk factor for myocardial infarction and stroke in older
adults. N. Engl. J. Med. 1999;340:14–22.

- O'Neill E, Sparrow CP, Chen Y, Eveland S, et al(2007)**Identification and characterization of MK-0859, a novel cholesteryl ester transfer protein inhibitor. *J Clin Lipidol*. 2007;1:367.
- Osende JJ, Badimon JJ, Fuster V, et al.(2001)** Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. *J Am Coll Cardiol*. 2001;38:1307-1312.
- Ostadal P, Alan D, Vejvoda J, Cepova J, Kukacka J,et al.,(2007)** Immediate effect of fluvastatin on lipid levels in acute coronary syndrome. *Mol Cell Biochem*. 2007;306:19–23. doi: 10.1007/s11010-007-9549-8
- Owen P, Garner J, Hergott L, Page RL II (2008).** Clopidogrel desensitization: case report and review of published protocols. *Pharmacotherapy* 2008;28:259–70.
- Parikh A, Lipsitz SR, Natarajan S.(2009)** Association between a DASH-like diet and mortality in adults with hypertension: findings from a population-based follow-up study. *Am J Hypertens*. 2009. Apr;22(4):409-416 Epub 2009 Feb 5
- Pasternak RC, Criqui MH, Benjamin EJ, et al. (2004)**Atherosclerotic Vascular Disease Conference: Writing Group 1: epidemiology. *Circulation*. 2004;109: 2605-2612 pathogenesis of atherothrombosis. *Am J Cardiovasc Drugs* 399-408
- Patrono, C., Garcia Rodriguez, L. A., Landolfi, R., & Baigent, C. (2005).** Lowdose aspirin for the prevention of atherothrombosis. *N Engl J Med* 353, 2373-2383.
- Pearson TA, Blair SN, Daniels SR, et al.(2002)** AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. *American Heart*

Association Science Advisory and Coordinating Committee. *Circulation*. 2002; 106:388-391.

Peters GR, Butler KA, Winter HR.(2006) Multiple-dose pharmacokinetics (PK) and pharmacodynamics (PD) of the reversible, orally active ADP receptor antagonist AZD6140 [abstract] *Eur Heart J*. 2006;27(Suppl 1):S758.

Petersen, S., Peto, V., Luengo-Fernandez, R., & Gray, A. (2005). European Cardiovascular Disease Statistics. London: British Heart Foundation.

Pinderski Oslund LJ, Hedrick CC, Olvera T, et al(1999) Interleukin-10 blocks atherosclerotic events in vitro and in vivo. *Arterioscler Thromb Vasc Biol*. 1999;19:2847–2853. [PubMed]

Pitt B, Remme W, Zannad F, et al.(2003) Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction *N Engl J Med*. 2003. Apr 3;;348(14):1309-1321 Epub 2003 Mar 31

Redgrave JN, Lovett JK, Gallagher PJ, Rothwell PM.(2006) Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms: the Oxford plaque study *Circulation* 2006;113:2320–2328.

Reilly MP et al. (2005) Resistin is an inflammatory marker of atherosclerosis in humans. *Circulation* 111: 932–939

Rendell M (2004). Advances in diabetes for the millennium: drug therapy of type 2 diabetes. *MedGenMed*. 2004;6(3 suppl):9 Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346(6):393-403

- Ridker PM et al. (2005)** Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. *JAMA* 294: 326–333
- Ridker PM, Danielson E, Fonseca FA, et al. (2008)** JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med.* 2008. Nov 20;;359(21):2195-2207 Epub 2008 Nov 9 [PubMed]
- Roberts HR, Monroe DM, Escobar MA (2004)** Current concepts of hemostasis: implications for therapy. *Anesthesiology.*;100:722-730.
- Roden DM, and Stein S (2009).** Clopidogrel and the concept of high-risk pharmacokinetics. *Circulation* 2009;119:2127
- Ross R (1999).** Atherosclerosis is an inflammatory disease. *N Engl J Med.* 1999;340:115–126. [PubMed]
- Ruggenenti P, Fassi A, Ilieva AP, et al (2004).** Preventing microalbuminuria in type 2 diabetes. *N Engl J Med.* 2004;351:1941–51.
- Rump LC (1999)** Advantages of Ang II receptor blockade over ACE inhibition with respect to suppression of sympathetic activity: heartening news for the kidney? *Nephrol Dial Transplant.* 1999;14:556–559. [PubMed]
- Ruttmann E et al. (2005)** γ -Glutamyltransferase as a risk factor for cardiovascular disease mortality. An epidemiological investigation in a cohort of 163 944 Austrian adults. *Circulation* 112: 2130–2137
- Sabatine MS.(2009)** Novel antiplatelet strategies in acute coronary syndromes. *Cleve Clin J Med.* 2009;76:8–14.
- Sabatine MS, Cannon CP, Gibson CM, et al (2005)** CLARITY-TIMI 28 Investigators Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *N Engl J Med.* 2005;352:1179-1189.

- Sacco RL, Diener HC, Yusuf S, et al (2008).** Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. *N Engl J Med* 2008;359:1238–51.
- Sacks FM, Bray GA, Carey VJ, et al. (February 2009).** "Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates". *N. Engl. J. Med.* 360 (9): 859–73. doi:10.1056/NEJMoa0804748. PMID 19246357.
- Sakuma H et al. (2005)** Assessment of coronary arteries with total study time of less than 30 minutes by using whole-heart coronary MR angiography. *Radiology* 237: 316–321
- Samara WM, Gurbel PA (2003)** The role of platelet receptors and adhesion molecules in coronary artery disease. *Coron Artery Dis.* 2003;14:65-79.
- Saunders E, Smith WB, DeSalvo KB, Sullivan WA.(2007)** The efficacy and tolerability of nebivolol in hypertensive African American patients. *J Clin Hypertens (Greenwich)* ;9(11):866-875
- Schieffer B, Bunte C, Witte J, et al (2004)** Comparative effects of AT₁-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. *J Am Coll Cardiol.* 2004;44:362–368.
- Schillinger M et al. (2005)** Inflammation and Carotid Artery—Risk for Atherosclerosis Study (ICARAS). *Circulation* **111**: 2203–2209
- Schleinitz MD, Heidenreich PA. (2005)** cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. *Ann Intern Med.* 2005;142:251-259.
- Schmieder RE, Hilgers KF, Schlaich MP, et al (2007)** Renin-angiotensin system and cardiovascular risk. *Lancet.* 2007;369:1208–1219.

- Schneider HJ, Glaesmer H, Klotsche J, et al. (2006)** DETECT Study Group Accuracy of anthropometric indicators of obesity to predict cardiovascular risk. *J Clin Endocrinol Metab.* 2007. Feb;92(2):589-594 Epub 2006 Nov 14
- Schuijf JD et al. (2006)** Meta-analysis of comparative diagnostic performance of magnetic resonance imaging and multislice computed tomography for noninvasive coronary angiography. *Am Heart J* 151: 404–411
- Schwartz GG, Olsson AG, Ezekowitz MD, et al. (2001)** Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. *JAMA* 2001;285(13):1711-1718
- Segrest JP, Jones MK, De Loof H, Dashti N (September 2001).** "Structure of apolipoprotein B-100 in low density lipoproteins". *Journal of Lipid Research* 42 (9): 1346–67. PMID 11518754.
- Serebruany VL(2006).** Dyspnoea after AZD6140: safety first? *Eur Heart J* 2006;27:1505–6.
- Sever PS, Poulter NR, Dahlöf B, et al.(2005)** Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). *Diabetes Care* 2005;28(5):1151-1157
- Shah T, Casas JP, Cooper JA et al (2009) :**Critical appraisal of CRP controlled trial. *JAMA.* 2002; 288: 321–333 thrombus formation. *Circ Res*;100:1261–75.
- Sipahi I, Tuzcu EM, Wolski KE, et al. (2008)** β -Blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. *Ann Intern Med.*;147(1):10-18
- Sirol M et al. (2005)** Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. *Circulation* 112: 1594–1600

- Skurk T, Hauner H(2004).** Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-i. *tnt J Obes Relat Metab Disord.* 2004;28:1357-1364.
- Smith A et al. (2005)** Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. *Circulation* 112: 3080–3087
- Smith SC, Jr, Allen J, Blair SN, et al. (2006)** AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update [published correction appears in *Circulation*. 2006;113(22):e847]
- Smith SC Jr, Greenland P, Grundy SM.(2000)** AHA Conference Proceedings. Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: executive summary. American Heart Association. *Circulation* 2000; 101: 111–6.
- Smith SC Jr, Jackson R, Pearson TA, et al.(2004)** Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. *Circulation.* 2004;109: 3112-3121.
- Soejima H, Ogawa H, Yasue H, et al.(1999)** Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. *Circulation.* 1999;99:2908-2913.
- Sorbera LA, Serradell N, Bolos J, Bayes M (2006).** Terutroban sodium. Prostanoid tp receptor antagonist, antithrombotic agent, antiatherosclerotic agent. *Drugs Future.* 2006;31:867–73. doi:0

- Soudijn, W; Van Wijngaarden, I; Ijzerman, AP (2007).** "Nicotinic acid receptor subtypes and their ligands". Medicinal research reviews 27 (3): 417–33. doi:10.1002/med.20102. PMID 17238156.
- Sposito, A. C., & Chapman, M. J. (2002).** Statin therapy in acute coronary syndromes. Mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 22, 1524-1534
- Spronk et al.,2004** Thrombosis Journal 2004 2:12 doi:10.1186/1477-9560-2-12
- Spuentrup E et al. (2005)** Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation 111: 1377–1382
- Stary, H. C., Chandler, A. B., Glagov, S., Insull,W., et al. (1995).** A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis.. American Heart Association. Circulation 92, 1355-1374.
- Steckelings UM, Kaschina E, Unger T (2005)** The AT₂receptor – a matter of love and hate. Peptides. 2005;26:1401–1409. [PubMed]
- Stein EA, Stroes ESG, Steiner G, Capponi AM, et al.(2009),**Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from five phase II clinical trials. Am J Cardiol. 2009;104:82–91. [PubMed]
- Steiner G (December 2007).** "Atherosclerosis in type 2 diabetes: a role for fibrate therapy?". Diab Vasc Dis Res 4 (4): 368–74. doi:10.3132/dvdr.2007.067. PMID 18158710.
- Steinhubl SR, Berger PB, Mann JT, III, et al.,(2002)** CREDO InvestigatorsEarly and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [published correction appears in JAMA. 2003;289:987]. JAMA. 2002;288:2411-2420
- Steinhubl, S., & Moliterno, D. J. (2005).** The role of the platelet in pathogenesis of atherothrombosis. Am J Cardiovasc Drugs 399-408

- Strychar I (January 2006).** "Diet in the management of weight loss". CMAJ 174 (1): 56–63. doi:10.1503/cmaj.045037. PMID 16389240. PMC 1319349.
- Suleiman M et al. (2005)** Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 54: 2802–2806
- Swedberg K, Eneroth P, Kjeksus J, et al (1990).** Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730–1736. [PubMed]
- Takaya N et al. (2005)** Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: a high-resolution magnetic resonance imaging study. Circulation 111: 2768–2775
- Takemoto, M., and Liao, J. (2001).** Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21, 1712–1719.
- Tantry US, Bliden KP, Gurbel PA. (2007)** AZD6140. Expert Opin Investig Drugs 2007;16:225–9.
- Taylor AJ et al. (2005)** Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three year outcomes in the Prospective Army Coronary Calcium (PACC) Project. J Am Coll Cardiol 46: 807–81
- Taylor AJ, Kent SM, Flaherty PJ et al (2002):** ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106:2055–2060.

- Tedgui, A., and Chapman, M. J. (2003).** Pathogenèse de l'athérosclérose : théories et mécanismes, L'athérosclérose: Physiopathologie, Diagnostics, Thérapeutiques (pp. 245-256). Paris: Masson.
- Tedgui, A., and Mallat, Z. (2001).** Atherosclérose et Inflammation. *Med Sci* 14, 162-169.
- Teo K, Yusuf S, Sleight P, et al (2004)** Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. *Am Heart J.* 2004;148:52–61. [PubMed]
- Teo KK, Ounpuu S, Hawken S, et al.(2006)** INTERHEART Study Investigators Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. *Lancet* 2006;36(9536):647-658
- Tontonoz, P., Nagy, L., Thomazy, V. A., & Evans, R. M. (1998)** PPAR gamma promotes monocyte-macrophage differentiation and uptake of oxidised LDL. *Cell* 93, 249-252
- Traub, O., and Berk, B. C. (1998).** Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force. *Arterioscler Thromb Vasc Biol* 18, 677-685.
- Tschope C, Gohlke P, Zhu YZ, et al (1997).** Antihypertensive and cardioprotective effects after angiotensin-converting enzyme inhibition: role of kinins. *J Card Fail.* 1997;3:133–148. [PubMed]
- Tsimikas S et al. (2005)** Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. *N Engl J Med* 353: 46–57

- Turnbull F (2003)** Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet*. 2003;362:1527–1535
- Tzoulaki I et al. (2005)** C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. *Circulation* 112: 976–983
- Vaisar T, Pennathur S, Green PS, Gharib SA, et al (2007).** Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. *J Clin Invest*. 2007;117:746–756. doi: 10.1172/JCI26206. [PMC free article] [PubMed] [Cross Re
- Vandenbroucke JP, Rosing J, Bloemenkamp KW(2001):** Oral contraceptives and the risk of venous thrombosis. *N Engl J Med*. 2001; 344: 1527–1535.
- Van deWerf, F., Ardissino, D., Betriu, A., Cokkinos, D. V., Falk, E., Fox, K. A., et al. (2003).** Task Force Report. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J* 24, 28-66.
- Vickrey BG, Rector TS, Wickstrom SL, et al.(2002)** Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. *Stroke*. 2002;33:901-906.
- Viles Gonzalez JF, Fuster V, Corti R, et al(2005).** Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition—a magnetic resonance imaging study. *Eur Heart J*. 2005;26:1557–61. doi: 10.1093/eurheartj/ehi175. [PubMed] [Cross Ref

- Vliegenthart R et al. (2005)** Coronary calcification improves cardiovascular risk prediction in the elderly. *Circulation* 112: 572
- Vowden P, Vowden K (2001).** "Doppler assessment and ABPI: Interpretation in the management of leg ulceration".
- Wagner DD, Burger PC (2003):**Platelets in inflammation and thrombosis. *Arterioscler Thromb Vasc Biol*;23:2131-2137.
- Waki H, Yamauchi T, Kadowaki T (February 2010).** "[Regulation of differentiation and hypertrophy of adipocytes and adipokine network by PPARgamma]" (in Japanese). *Nippon Rinsho* 68 (2): 210–6. PMID 20158086.
- Walker C, Reamy BV (April 2009).** "Diets for cardiovascular disease prevention: what is the evidence?". *Am Fam Physician* 79 (7): 571–8. PMID 19378874.
- Wallentin L, Becker RC, Budaj A, et al (2009).** Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2009;**361**:1045–1057.
- Wallentin L, Varenhorst C, James S, et al (2008)** Prasugrel achieves greater and faster P2Y₁₂ receptor mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. *Eur Heart J*. 2008;29:21–30. [PubMed]
- Warnick GR, Knopp RH, Fitzpatrick V, Branson L (January 1990).** "Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints". *Clinical Chemistry* **36** (1): 15–9. PMID 2297909.
- Weber C, Zernecke A, Libby P (2008).** The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. *Nat Rev Immunol*. 2008;8:802–15.
- Weintraub WS, Mahoney EM, Lamy A, et al (2005).** Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute

coronary syndromes without ST-segment elevation. *J Am Coll Cardiol.* 2005;45: 838-845.

Williams, K. J., and Tabas, I. (1995). The response-to-retention hypothesis of early atherogenesis. *Arterioscler Thromb Vasc Biol* 15, 551-561.

Willoughby S, Holmes A, Loscalzo J (2002) Platelets and cardiovascular disease. *Eur J Cardiovasc Nurs.* 2002;1:273-288.

Wing LM, Reid CM, Ryan P, et al. (2003) Second Australian National Blood Pressure Study Group *N Engl J Med.*;348(7):583-592

Wiviott SD, Braunwald E, McCabe CH, et al.(2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med.* 2007;357:2001–2015. [PubMed]

Wiviott SD, Cannon CP, Morrow DA, et al.,(2006) PROVE IT-TIMI 22 Investigators Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy [published correction appears in *J Am Coll Cardiol.* 2006;47(2):472] *J Am Coll Cardiol.*;46(8):1411-1416

Wolff T, Miller T, Ko S.(2009) Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2009;150(6):405-410 [PubMed]

Worth NF, Berry CL, Thomas AC, Campbell JH. S18886 (2005), a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. *Atherosclerosis.* 2005;183:65–73. doi: 10.1016/j.atherosclerosis.2005.02.034. [PubMed] [Cross Ref]

Yokoyama M, Origasa H, Matsuzaki M, et al.(2007) Japan EPA Lipid Intervention Study (JELIS) Investigators Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a

randomised open-label, blinded endpoint analysis [published correction appears in Lancet. 2007;370(9583):220] Lancet 2007;369(9567):1090-1098

Yusuf S, Hawken S, Ounpuu S, et al(2004):Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.

Yusuf S, Hawken S, Ounpuu S, et al(2005): Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study Lancet 2005;366:1640–1649.

Yusuf S, Sleight P, Pogue J, et al (2000). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153. [PubMed]

Yusuf S, Zhao F, Mehta SR, Chrolavicius S, ET AL (2001) Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [published corrections appear in N Engl J Med. 2001;345:1506 and 1716]. N Engl J Med. 2001;345:494-502.

ZhengZJ, Sharrett AR, Chambless LE et al.(1997) Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 1997;131:115–12